We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Liver Enzymes Increase Diabetes Risk for Hispanic Adults

By LabMedica International staff writers
Posted on 08 Apr 2021
Print article
Image: Elevated liver enzymes are associated with incident diabetes in US Hispanic/Latino adults (Photo courtesy of Judy George, BA, MBA)
Image: Elevated liver enzymes are associated with incident diabetes in US Hispanic/Latino adults (Photo courtesy of Judy George, BA, MBA)
Non‐alcoholic fatty liver disease (NAFLD) has been associated with increased risk of incident diabetes, but such evidence is lacking in the Hispanic/Latino population, which has high prevalence of obesity and NAFLD.

NAFLD, also known as metabolic (dysfunction) associated fatty liver disease (MAFLD), is excessive fat build-up in the liver without another clear cause such as alcohol use. There are two types; non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), with the latter also including liver inflammation.

Medical Scientists at the Albert Einstein College of Medicine (Bronx, NY, USA) analyzed data from 6,928 adults participating in the Hispanic Community Health Study/Study of Latinos (mean age, 38 years). Participants did not have diabetes at a baseline visit from 2008 to 2011 and returned for a follow-up examination a mean six years after baseline from 2014 to 2017. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) levels were measured at baseline. The team placed participants into quartiles for ALT, AST and GGT based on their baseline levels. Incident diabetes was identified at follow-up through laboratory measurements or the use of diabetes medication.

The scientists reported that of the 738 participants who had diabetes during follow-up, 533 were identified through blood tests. Adults were more likely to develop diabetes if they were men, older or of Puerto Rican background or had a lower education level, higher BMI, higher waist circumference or a lower score on an alternative healthy eating index. adults in the highest ALT quartile had a greater risk for developing diabetes compared with those in the lowest quartile (Relative Risk [RR] = 1.51). Participants in the highest quartile for GGT also had an increased risk for diabetes at follow-up compared with the lowest quartile (RR = 2.39). Both associations remained after adjusting for baseline fasting glucose. After adjusting for homeostatic model assessment of insulin resistance, only a high GGT level was significantly associated with incident diabetes.

The risks for incident diabetes with ALT and GGT were similar for all Hispanic backgrounds except for Dominican ethnicity. ALT and GGT were both associated with incident diabetes regardless of obesity status. Those who had a high ALT and were light or moderate alcohol drinkers had an increased risk for incident diabetes (RR = 1.5), but there was no increased risk for those who did not drink. In addition to using liver enzyme testing to screen Hispanic adults for their diabetes risk, the findings revealed that lifestyle modifications can reduce a person’s risk for both NAFLD and diabetes.

Carmen R. Isasi, MD, PhD, FAHA, an associate professor and the senior author of the study, said, “Hispanics are at high risk of diabetes and its complications and are also at high risk for nonalcoholic fatty liver disease (NAFLD). Liver enzymes could be a simple clinical tool to screen individuals for diabetes risk, in addition to traditional factors.”
The authors concluded that higher ALT and GGT levels are associated with increased risk of developing diabetes among Latinos. Liver enzyme tests might aid in diabetes prevention by identifying high‐risk individuals. The study was originally published online on January 21, 2021 in the journal Diabetic Medicine.

Related Links:
Albert Einstein College of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.